Art. 30 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 5×
1.

A Committee for Medicinal Products for Veterinary Use is hereby established. The Committee shall be part of the Agency.

2.

Without prejudice to Article 56 and other tasks which Union law may confer on it, in particular under Regulation (EEC) No 2377/90 [Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Union procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (OJ L 224, 18.8.1990, p. 1). Regulation as last amended by Commission Regulation (EC) No 1029/2003 (OJ L 149, 17.6.2003, p. 15).], the Committee for Medicinal Products for Veterinary Use shall be responsible for drawing up the opinion of the Agency on any question concerning the admissibility of files submitted in accordance with the centralised procedure, the granting, variation, suspension or revocation of an authorisation to place a veterinary medicinal product on the market arising in accordance with the provisions of this Title, and pharmacovigilance.

3.

At the request of the Executive Director of the Agency or the Commission representative, the Committee for Medicinal Products for Veterinary Use shall also draw up opinions on any scientific matters concerning the evaluation of veterinary medicinal products. The Committee shall take due account of any requests from Member States for an opinion. The Committee shall also formulate an opinion whenever there is disagreement in the assessment of a veterinary medicinal product through the mutual recognition procedure. The opinion of the Committee shall be made publicly accessible.

  • Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009…3Law

    … het Comité voor geneesmiddelen voor diergeneeskundig gebruik (het comité), die ingesteld zijn bij respectievelijk de artikelen 55 en 30 van Verordening (EG) nr. 726/2004. Aanvragers van een vergunning voor het in de handel brengen van …

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    En premier lieu, il convient de rappeler que, en application de l’article 56, paragraphe 2, du règlement n o 726/2004, le CHMP peut instituer des GSC dans le cadre de l’évaluation de types particuliers de médicaments ou de …

    2 Mar 2022 · 62020TJ0556

  • Regulation (EU) 2019/5Lawamends

  • Opinion of Advocate General Medina delivered on 7 September 2023. Debregeas et associés Pharma (D & A Pharma) v European Commission and EuroDecision

    As a preliminary point, it should be recalled that, as is apparent from paragraphs 45 to 48 of the judgment under appeal, pursuant to Article 56(2) of Regulation No 726/2004, the CHMP may establish SAGs in connection with the evaluation of …

    7 Sep 2023 · 62022CC0291

  • College van Beroep voor het bedrijfsleven, 30-09-2025, 23/346Decision

    … het Comité voor geneesmiddelen voor diergeneeskundig gebruik (het comité), die ingesteld zijn bij respectievelijk de artikelen 55 en 30 van Verordening (EG) nr. 726/2004. Aanvragers van een vergunning voor het in de handel brengen van …

    30 Sep 2025 · ECLI:NL:CBB:2025:537